Drug Profile
KNK 002
Alternative Names: CSTD 002 NK; CSTD002; K-NK002; mbIL21 ex-vivo expanded donor-derived NK cellsLatest Information Update: 12 Dec 2022
Price :
$50
*
At a glance
- Originator CytoSen Therapeutics
- Developer Kiadis Pharma; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 12 Dec 2022 No development reported - Phase-II for Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (Sanofi pipeline; December 2022)
- 12 Dec 2022 No development reported - Phase-II for Chronic myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (Sanofi pipeline; December 2022)
- 12 Dec 2022 No development reported - Phase-II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (Parenteral) (Sanofi pipeline; December 2022)